SCHEMBL10160837

SCHEMBL10160837

Cc1cc2c(Br)cccc2c(OC(=O)OC(C)(C)C)c1C(=O)Oc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.36
MAPT P10636 10/20 0.36
RAB9A P51151 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
POLB P06746 1/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP2C9 P11712 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
TDP1 Q9NUW8 3/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 2/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
PTK2B Q14289 1/20 0.32
HTT P42858 2/20 0.32
KDM4E B2RXH2 2/20 0.32
TP53 P04637 1/20 0.32
GAA P10253 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10161353 0.86 POLB (0.38) ELANEMAPTRAB9ANPSR1POLB
SCHEMBL10160835 0.84 L3MBTL1 (0.41) MAPTRAB9ANPSR1POLBL3MBTL1
SCHEMBL10161368 0.83 POLB (0.35) ELANEMAPTRAB9ANPSR1POLB
SCHEMBL10160466 0.82 MAPT (0.36) ELANEMAPTRAB9ANPSR1POLB
SCHEMBL10161454 0.79 MAPT (0.39) ELANEMAPTRAB9ANPSR1POLB
SCHEMBL10161340 0.79 THRA (0.42) MAPTTDP1LMNAHPGDTP53
SCHEMBL10196582 0.78 THRA (0.40) MAPTCYP1A2CYP2C19L3MBTL1KMT2A
SCHEMBL10161469 0.76 ELANE (0.33) ELANEMAPTRAB9ANPSR1POLB
SCHEMBL10160980 0.76 MEN1 (0.39) ELANEMAPTCYP1A2CYP2C19CYP2C9
SCHEMBL10161192 0.74 MAPT (0.36) ELANEMAPTCYP1A2CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115819-A1 Pentacycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-05-10 US disclosed
US-20120115819-A1 Pentacycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-05-10 US disclosed
WO-2010132670-A2 PENTACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115819-A1 Pentacycline Compounds TSLP, IL5, IL17A ELANE 841/4885MAPT 734/4885RAB9A 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.